ClinicalTrials.gg
CompletedNCT01570933NIVNAVAUpdated Dec 9, 2013

Feasibility Study Over the NAVA Mode in Noninvasive Ventilation After Cardiac Surgery in Infants.

A Phase 4 interventional study of NivNava and Cpap in Heart Defects, Congenital and Surgery, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Completed at 1 site in Belgium. Open to participants aged Up to 12 Months. Per ClinicalTrials.gov, last updated 2013-12-09.

Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
Up to 12 Months
Sex
All
01

Study summary

Neonates who underwent cardiac surgery with cardiopulmonary bypass almost always require non-invasive respiratory support (NIV) in relay to conventional ventilation. Current nasal interfaces do not generally allow synchronised bilevel ventilation. NIV-NAVA mode allows, through an oesophageal catheter, to record the electrical activity of the diaphragm and thereby synchronize breaths from the ventilator on the inspiratory efforts of the child. Moreover, the pressure support delivered by the ventilator may be proportional to the diaphragmatic effort developed by the child. This mode, associated with the interface Miniflow®, could increase the comfort of the child by allowing a more efficient synchronization and reducing its respiratory work. To our knowledge, this ventilation mode with this interface has not been evaluated in the postoperative period of cardiac surgery in the newborns. The purpose of this study is to evaluate the feasibility of this ventilatory mode and evaluate its influence on ventilatory parameters of this category of infants.

Read the detailed description

Study Design:

Single centre prospective crossover study

Study Objectives:

Main objectives:

  • Assessment of the feasibility of non invasive ventilation in NIV-NAVA mode via Miniflow® interface in infants of less than 3.5 kg after cardiac surgery with cardiopulmonary bypass.
  • Evaluation of the following parameters:

    • Implementation of the interface
    • Air leaks
    • Placement and contention of oesophageal probe
    • Quality of synchronization
    • Obstruction of the probe
    • Risk of nasal wounds

Secondary objectives:

  • Comparison of ventilation parameters between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode
  • Evaluation of the following parameters:

    • Breathing rhythm
    • Tidal volume
    • PEEP
    • Inspiratory pressure
    • FiO2
    • PaO2
    • PaCO2
    • pH
  • Evolution of EAdi min and EAdi max parameters in NIV-NAVA mode (EAdi : diaphragmatic electric activity)

Conduct of the study:

First phase: placement of EADI catheter and extubation

When extubation criteria are met, the oesophageal EADI catheter is placed according to the manufacturer's instructions. The ventilation mode is then switched to Pressure Support Mode with the same Peep as in the previous mode and a pressure support of 10 cmH2O.

During 30 minutes, trends in respiratory rate, tidal volume, PEEP, inspiratory pressure, FiO2, EADI min, EADi max are recorded.

After 30 minutes, an arterial blood gas analysis is performed to determine the values of PaCO2, PaO2 and pH before randomization.

The child is extubated according to the procedures of the service and the non-invasive ventilation relay is introduced through the Miniflow® interface with nasal prongs adapted to the morphology of the child. An adrenaline nebulisation can be given before starting NIV in case of respiratory distress due to laryngeal oedema.

Second phase: nCPAP or NIV-NAVA

Following randomisation, the child is included in the "nCPAP first" arm or "NIV-NAVA first" arm and is ventilated in the designated mode for 30 minutes. During the first 15 minutes, the ventilation parameters are adapted according to the procedures below:

nCPAP parameters adaptation:

  • PEEP and FiO2 as previously set in invasive ventilation;
  • FiO2 according to target SpO2 values of the child and/or 10% higher than FiO2 in invasive ventilation mode;
  • PEEP between 4-6 cmH2O in order to minimize respiratory efforts.

NIV-NAVA parameters adaptation:

  • PEEP and FiO2 as previously set in invasive ventilation;
  • Adaptation of the NIV-NAVA level to reach a EADi level equal to the mean EADi level over the last 5 minutes of the invasive mode. Inspiratory pressure and tidal volume are limited respectively to 30 cmH2O and 8 ml/kg.
  • FiO2 according to target SpO2 values of the child and/or 10% higher than FiO2 in invasive ventilation mode ;
  • PEEP between 4-6 cmH2O in order to minimize respiratory efforts.

Over the last 15 minutes of this ventilation mode, trends in respiratory rate, tidal volume, PEEP, inspiratory pressure, FiO2, EADI min, EADi max are recorded.

On Minutes M16, M21 and M29 in NIV-NAVA mode, synchronisation data are recorded : auto-triggering, double triggering, inspiration beginning and ending.

After 30 minutes, an arterial blood gas analysis is performed to determine the evolution of the values of PaCO2, PaO2 and pH.

At any time, if the re-intubation criteria are met, the child is re-intubated and returned to conventional ventilation. He is then excluded of the study.

Third phase: nCPAP or NIV-NAVA

The ventilation mode is changed from nCPAP to NIV-NAVA or from NIV-NAVA to nCPAP. The adaptation protocol and the recorded parameters are the same as in the second phase.

After 30 minutes, an arterial blood gas analysis is performed to determine the evolution of the values of PaCO2, PaO2 and pH.

At any time, if the re-intubation criteria are met, the child is re-intubated and returned to conventional ventilation. He is then excluded of the study.

Fourth phase: end of the study

The study concludes at the end of the third phase. The child is left in the better tolerated ventilation mode, as judged by the clinician.

02

Conditions studied

  • Heart Defects, Congenital
  • Surgery

Keywords

  • cardio-pulmonary bypass
03

In context

Heart Defects, Congenital

1,031 studies on the registry are indexed under Heart Defects, Congenital; 262 are open to participants now.

This study's enrollment of 10 is below the median of 60 across 531 interventional studies indexed under Heart Defects, Congenital.

Browse Heart Defects, Congenital studies →

Lead sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 348 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight ≤ 5 kg
  • Postoperative period of cardiac surgery with cardiopulmonary bypass (max 10 days after surgery)
  • Conventional ventilation
  • Agreement with the extubation criteria
  • Arterial line

Exclusion criteria

Exclusion Criteria:

  • High frequency oscillation ventilation
  • Extubation criteria not fulfilled
  • Proven or suspected sepsis
  • Absence of arterial line
  • Oesophageal pathology (Excepted gastro-oesophageal reflux)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    NAVAfirst

    Starting crossover by NIVnava mode

    Device: NivNava

  • Active comparator
    Cpap first

    Start crossover by Cpap on nasal canula

    Device: Cpap

Interventions

  • DeviceNivNava

    Non-invasive Nava ventilation mode on nasal cannula

    Also known as: Neurally adjusted ventilatory assist

  • DeviceCpap

    nasal Cpap on nasal cannula

    Also known as: InfantFlow(R), CareFusion(R), SanDiego, Ca, USA

06

What researchers measure

Primary outcomes

  1. Evaluation of the percentage of asynchronies during the nava mode

    One of the aims of the NAVA mode is to provide better synchronization between the child's breathing needs and the breathing cycles given by the ventilator. By comparing the EDI curve (electric activity of the diaphragm of the child) and the flow and pressure curves of the ventilator, it is possible to determine the percentage of asynchronies during the nava mode

    Time frame: from minute zero to minute 90

Secondary outcomes

  1. Comparison of breathing rhythm between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode

    Time frame: from minute zero to minute 90

  2. Comparison of PEEP (positive end expiratory pressure) between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode

    Time frame: from minute zero to minute 90

  3. Comparison of Inspiratory Pressure between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode

    Time frame: from minute zero to minute 90

  4. Comparison of FiO2 between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode

    Time frame: from minute zero to minute 90

  5. Comparison of PaO2 between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode

    Time frame: from minute zero to minute 90

  6. Comparison of PaCO2 between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode

    Time frame: from minute zero to minute 90

  7. Comparison of blood pH between nasal Continuous Positive Airway Pressure (nCPAP) mode and NIV-NAVA mode

    Time frame: from minute zero to minute 90

07

Study locations

1 site
  • Cliniques Univeristaires Saint-Luc
    Brussels, 1200, Belgium
08

References and documents

Publications

  • Houtekie L, Moerman D, Bourleau A, Reychler G, Detaille T, Derycke E, Clement de Clety S. Feasibility Study on Neurally Adjusted Ventilatory Assist in Noninvasive Ventilation After Cardiac Surgery in Infants. Respir Care. 2015 Jul;60(7):1007-14. doi: 10.4187/respcare.03624. Epub 2015 Feb 17. PubMed 25691764 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2012
First posted
Apr 4, 2012
Start
Nov 2011
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Last update
Dec 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01570933
Responsible party
Sponsor
First posted
Apr 4, 2012
Start date
Nov 2011
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Dec 9, 2013

Study contacts

Laurent Houtekie, md
principal investigator · Cliniques Universitaires Saint-LUc, Brussels

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion